Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

As Wall Street puts April's tariff shakeout in the rearview mirror and indexes set record highs, investors remain wary of U.S ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

European stock markets surged at Tuesday's open, with investors embracing a significant relief rally fueled by an ...

Futures data from IG suggests a choppy start for European markets, with London's FTSE looking set to open 0.3% lower at 8,747 ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...

Weight loss drugs, including Wegovy (semaglutide) and Mounjaro (tirzepatide), are becoming increasingly popular among those trying to lose weight. But a rise in so-called "Ozempic babies" has led ...

Team Germany has announced the first six players of to their roster for the 2026 Winter Olympics. The remainder of the rosters will be announced later this year. The tournament will consist of 12 ...

Discover why Hims & Hers is leading the telehealth market with strong growth, a loyal user base, and expansion into new health segments.

Dive Insight: Though Novo is a pioneer in the development of in-demand obesity medicines, it currently finds itself on the defensive.Zepbound’s fast launch has eroded Wegovy’s market share, and Novo’s ...